Breaking Down Guizhou Bailing Group Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Rooted in Anshun since its establishment in August 1970 and listed on the Shenzhen Stock Exchange under 002424.SZ, Guizhou Bailing Group Pharmaceutical Co., Ltd. combines a deep heritage in Miao medicines with modern pharmaceutical ambition-boasting roughly 6,586 employees, a presence in over 30 Chinese provinces and exports to more than 20 countries-while delivering a robust financial performance of ¥2.45 billion revenue in 2022 (a 10% year‑over‑year rise) and ¥450 million net profit, underpinned by an R&D commitment equal to 8% of revenue that fuels over 20 recent patent applications; the company's mission to improve healthcare, vision to bridge traditional Chinese and modern medicines, and core values-highlighting innovation, a 98% product inspection pass rate, 85% customer satisfaction, and sustainability gains such as a 15% reduction in water use and 20% less waste-frame a compelling story of growth, responsibility, and scientific pursuit

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Intro

• Founded: August 1970
• Headquarters: Anshun, Guizhou Province
• Stock listing: Shenzhen Stock Exchange, June 2010 (002424.SZ)
• Employees: ~6,586
• Geographic reach: >30 provinces in China; exports to >20 countries

• Preserve and modernize Miao herbal medicine traditions while ensuring product safety, efficacy and accessibility.
• Deliver reliable, evidence-based TCM and integrated formulations for mainstream clinical use.
• Create long-term value for stakeholders through sustainable growth, innovation and social responsibility.

• Be a globally respected leader in ethnic pharmaceutical heritage and modern Chinese medicine innovation.
• Expand international market presence while maintaining leadership in domestic therapeutic categories tied to Miao medicine.
• Achieve science-driven integration of traditional formulations with modern quality, manufacturing and regulatory standards.

• Heritage & Innovation - respect traditional knowledge; apply modern R&D rigor.
• Quality & Safety - comply with GMP and regulatory best practices across all products.
• Sustainability & Responsibility - reduce environmental footprint and support local communities.
• Patient-centricity - prioritize clinical effectiveness and accessibility.
• Collaboration & Talent - invest in teams, partnerships and research networks.

• Strengthen clinical evidence for flagship Miao and TCM products through trials and real‑world data.
• Advance formulation technology for tablets, granules, oral liquids and novel delivery systems.
• Increase international registration and export scale into targeted Asian, African and Latin American markets.
• Maintain R&D intensity - R&D expenses ≈ 8% of total revenue in 2022 - focused on TCM modernization and formulation science.

• Diversified manufacturing capabilities across multiple dosage forms to address broad therapeutic needs.
• Robust distribution network enabling nationwide penetration and growing international sales.
• Targeted investments in green manufacturing that delivered measurable reductions in water use and waste.
• Focused human capital strategy to retain talent for ethnopharmacology, formulation science and regulatory affairs.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Overview

• Guizhou Bailing Group Pharmaceutical Co., Ltd. aims to improve healthcare through the development and production of innovative medicines, emphasizing quality, innovation, and customer satisfaction.
• The company is committed to corporate social responsibility, striving to contribute positively to society while maintaining sustainable business practices.

• To be a leading, trusted pharmaceutical group that bridges traditional Chinese medicine and modern pharmaceutical science to deliver safe, effective, and accessible therapies worldwide.
• To continually elevate manufacturing standards, expand global reach, and foster long-term value for patients, healthcare partners, and shareholders.

• Quality first: rigorous quality control across R&D, production, and distribution.
• Innovation-driven: sustained investment in research to develop differentiated products.
• Patient-centricity: product decisions guided by patient safety and clinical benefit.
• Integrity and compliance: adherence to regulatory standards and ethical practices.
• Sustainability: reducing environmental footprint and promoting responsible resource use.

• R&D expenses were approximately 8% of total revenue in 2022, signaling a robust commitment to pipeline development.
• Primary scientific concentration: integration of traditional Chinese medicine (TCM) formulations with modern delivery systems and formulation technologies.
• Strategic partnerships and internal programs target both new TCM-derived compounds and reformulation of existing products to improve efficacy and patient adherence.

• Implemented environmentally friendly production techniques-achieved a 15% reduction in water usage and 20% reduction in waste generation over two years.
• Ongoing programs to improve workplace safety, product accessibility, and community health education initiatives in regional markets.

• Scale R&D to convert TCM advantages into globally competitive therapies.
• Continue operational efficiencies to sustain profitability while expanding product mix.
• Enhance ESG disclosures and further reduce environmental impacts across manufacturing sites.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) - Mission Statement

• Advance healthcare through innovative and evidence-based medicines that combine TCM and modern formulations.
• Expand global reach while maintaining quality, compliance and affordability for diverse patient populations.
• Operate sustainably-minimizing environmental footprint and maximizing social contribution.

• Domestic footprint: distribution network covering over 30 provinces across China.
• International reach: exports to more than 20 countries, with growing presence in Asia, Africa and selected European markets.
• R&D focus: targeted investment in TCM modernization and novel formulation technologies.

• Increase R&D productivity: prioritize clinical validation and scalable formulation processes that bridge TCM and modern pharmacology.
• Optimize distribution and export channels to convert provincial coverage into deeper market penetration abroad.
• Scale sustainability measures-extend water and waste reductions across additional sites and report progress transparently.
• Strengthen partnerships with academic, clinical and regulatory stakeholders to accelerate global registration and adoption.

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ) Vision Statement

• Mission: Develop high-quality therapeutics and vaccines through science-led R&D, scalable manufacturing, and patient-centric services.
• Strategic Goal (3-5 years): Expand R&D pipeline, increase export footprint, and improve operational efficiency to support annual revenue growth and long-term profitability.
• Stakeholder Commitment: Create value for patients, healthcare partners, employees, shareholders, and communities.

• Innovation: Guizhou Bailing emphasizes the development of new medications, submitting over 20 patent applications in the past year and allocating a rising share of revenue to R&D.
• Quality: Committed to GMP-level manufacturing with a 98% pass rate on product inspections across production batches.
• Customer Satisfaction: Maintains continuous feedback loops with healthcare providers, achieving an 85% customer satisfaction rating.
• Sustainability: Implemented environmentally friendly production techniques, reducing water usage by 15% and waste generation by 20% over the past two years.
• Social Responsibility: Balances growth with community health initiatives and ethical supplychains.
• Employee Development: Invests in staff training programs and internal mobility to foster a culture of continuous improvement and innovation.

• R&D Acceleration: Increase annual patent filings and progress at least 3 drug candidates into clinical trials within the next 36 months.
• Quality & Compliance: Maintain ≥98% inspection pass rate and achieve additional international certifications to support export growth.
• Customer & Market Expansion: Improve customer satisfaction from 85% toward 90% via expanded provider programs and digital engagement.
• Sustainability Targets: Further reduce water usage by an additional 10% and waste by 15% over the next two years.
• Workforce Development: Scale training hours per employee by 25% year-over-year to support innovation culture.